Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Scott A TomlinsNickolay A KhazanovBenjamin J BulenDaniel H HovelsonMelissa J ShreveLaura E LambMarc R MatranaMark E BurkardEddy Shih-Hsin YangWilliam Jeffery EdenfieldE Claire DeesAdedayo A OnitiloMichael A ThompsonGary L BuchschacherAlan M MillerAlexander MenterBenjamin ParsonsTimothy WassenaarLeon C HwangJ Marie SugaRobert SiegelWilliam IrvinSuresh NairJennifer N SlimJamal MislehJamil KhatriGregory MastersSachdev ThomasMalek SafaDaniel M AndersonKat KwiatkowskiKhalis MitchellTina Hu-SeligerStephanie DreweryAndrew FischerKomal PlouffeEric CzuprenskiJennifer HippTravis ReederHana VakilD Bryan JohnsonDaniel R RhodesPublished in: Communications medicine (2023)
The validated, predictive, pan-tumor IRS model can expand PD-(L)1 monotherapy benefit outside currently approved indications.
Keyphrases